Systematic evaluation of cancer‐specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts
Autor: | Yishuo Wu, Zhuqing Shi, Quanwa Bao, Haifei Jia, Chelsea Perschon, David Duggan, Brian T. Helfand, Xiaoling Lin, Hongjie Yu, Jianfeng Xu, Siqun L. Zheng |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
Male
0301 basic medicine Oncology Cancer Research medicine.medical_specialty Genotype Population Single-nucleotide polymorphism Polymorphism Single Nucleotide genetic risk score lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Genotype-phenotype distinction Prostate Neoplasms Internal medicine Cancer screening Odds Ratio medicine Electronic Health Records Humans cancer Genetic Predisposition to Disease Public Health Surveillance Radiology Nuclear Medicine and imaging education Thyroid cancer Alleles Genetic Association Studies Original Research education.field_of_study Genome Human business.industry fungi Genomics Odds ratio medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis age at diagnosis Female Risk assessment business Cancer Prevention |
Zdroj: | Cancer Medicine, Vol 8, Iss 6, Pp 3196-3205 (2019) Cancer Medicine |
ISSN: | 2045-7634 |
Popis: | Background Genetic risk score (GRS) is an odds ratio (OR)‐weighted and population‐standardized method for measuring cumulative effect of multiple risk‐associated single nucleotide polymorphisms (SNPs). We hypothesize that GRS is a valid tool for risk assessment of most common cancers. Methods Utilizing genotype and phenotype data from The Cancer Genome Atlas (TCGA) and Electronic Medical Records and Genomics (eMERGE), we tested 11 cancer‐specific GRSs (bladder, breast, colorectal, glioma, lung, melanoma, ovarian, pancreatic, prostate, renal, and thyroid cancer) for association with the respective cancer type. Cancer‐specific GRSs were calculated, for the first time in these cohorts, based on previously published risk‐associated SNPs using the Caucasian subjects in these two cohorts. Results Mean cancer‐specific GRS in the population controls of eMERGE approximated the expected value of 1.00 (between 0.98 and 1.02) for all 11 types of cancer. Mean cancer‐specific GRS was consistently higher in respective cancer patients than controls for all 11 types of cancer (P 1.5, respectively), significant dose‐response associations of higher cancer‐specific GRS with higher OR of respective type of cancer were found for nine types of cancer (P‐trend |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |